Switzerland-based Vifor Pharma last week announced its financial performance in the first six months of the year. This has been so positive that the company’s shares increased by 3% (Zurich). The company’s revenue increased by 23.4% to CHF747m, with a CHF192m EBITDA, that is +44% vs H1 2017, far exceeding analysts’ expectations. Excellent performances–CHF229m sales–came from Mircera, developed by Roche and marketed in the US by Vifor and Fresenius, whose sales increased by 29%. The only negative is that hyperkalemia treatment Veltassa reported a 52% revenues increase–to CHF35m–that is 24% lower than analysts’ predictions. The management has announced a current-year guidance improvement: it now expects revenues to increase by 15% vs 2017, and EBITDA to increase by 25%.
(Source: Finanz und Wirtschaft)